MedTrace Logo

Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy

NCT01233128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 121

Last updated 2012-04-09

No results posted yet for this study

Summary

This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injections for patients with polypoidal choroidal vasculopathy.

Conditions

  • Age-Related Macular Degeneration

Sponsors & Collaborators

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • In Taek Kim, M.D. · Kyungpook National University Hospital

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233128 on ClinicalTrials.gov